Summary:
Researchers at the University of California, San Francisco (UCSF) have identified a set of 16 blood proteins whose levels change sharply during the menopausal transition. These molecular changes align with hormonal fluctuations—particularly in estradiol and follicle-stimulating hormone (FSH)—rather than with chronological age alone. In separate analyses of nearly 12,000 older women, higher midlife levels of these same biomarkers were associated with poorer cognitive performance and a roughly 15% greater risk of developing Alzheimer’s disease years later.
Key Facts:
- Hormone-driven signatures: Shifts in the 16 circulating proteins tracked closely with changes in estradiol and FSH across reproductive stages, using STRAW+10 staging rather than chronological age.
- Long-term predictive value: In pooled cohorts of nearly 12,000 older women, those with the highest levels of the menopause-associated proteomic profile showed worse memory and thinking skills and an estimated 15% increase in Alzheimer’s risk.
- Persistent inflammation: Vasomotor symptoms such as hot flashes and night sweats corresponded with pronounced increases in inflammatory proteins during midlife that were detectable decades later in older participants.
Source: University of California, San Francisco (UCSF)
Hot flashes, disrupted sleep, anxiety and intermittent memory lapses—often described as “brain fog”—are common complaints during the menopause transition. With about two-thirds of Alzheimer’s diagnoses occurring in women, researchers are investigating whether menopause-related biology contributes to this disparity beyond differences in lifespan.
Alzheimer’s disease pathology accumulates silently for decades before clinical symptoms appear. Because menopause involves a major endocrine shift in midlife, scientists have long suspected it may mark a biological window that influences long-term brain health.
In a study published in Nature Medicine, teams from the UCSF Fein Memory and Aging Center and the University of Toronto report that menopause leaves a reproducible molecular fingerprint in blood: 16 circulating proteins that reflect inflammatory, synaptic, metabolic and Alzheimer’s-related processes and that align with hormone changes during the transition.
“We don’t think that menopause is directly causing dementia,” said Kaitlin Casaletto, Ph.D., associate professor at the UCSF Fein Memory and Aging Center and co-senior author of the study. “But it’s possible that we may be able to predict a woman’s risk for dementia decades later by the levels of these molecules around menopause.”
Mapping the Molecular Dynamics of Menopause
Instead of treating menopause as a single event defined by the final menstrual period, the researchers used the STRAW+10 staging system to capture the years-long endocrine transition. They analyzed 80 women in their 40s and 50s across pre-, peri- and postmenopausal stages using multiplex assays that measured more than 100 blood proteins linked to neurodegeneration, inflammation and vascular health.
From this panel, 16 proteins consistently shifted across reproductive stages. Two prominent patterns emerged:
- Estradiol decline and inflammation: Falling estradiol levels during the transition correlated with increases in systemic inflammatory proteins.
- FSH rise and Alzheimer’s-linked proteins: Rising FSH levels occurred alongside higher abundance of proteins tied to amyloid- and tau-related biological pathways implicated in Alzheimer’s disease.
The team validated these proteomic patterns in a larger sample of more than 2,800 women from the UK Biobank, confirming broader menopause-related upregulation of inflammatory and catabolic processes and signs of accelerated cellular and organ aging, including signals related to brain aging.
Long-Term Cognitive Repercussions
To test whether these midlife proteomic shifts predicted later cognitive outcomes, the authors examined archived data from four longitudinal cohorts totaling nearly 12,000 women in their 60s and 70s. Women with the highest proteomic scores linked to menopause performed worse on memory and cognitive tests and faced about a 15% higher risk of subsequent Alzheimer’s disease compared with women with lower scores.
The study further linked clinical menopause symptoms to the molecular signature. Women who reported severe night sweats or hot flashes during midlife showed the largest elevations in inflammatory proteins, and those inflammatory traces were still detectable decades later in older women who recalled severe vasomotor symptoms.
A Critical Window for Early Intervention
Preliminary analyses in men showed a related molecular profile, but it evolved gradually across decades instead of the abrupt endocrine-driven changes observed in women. This contrast suggests that menopause may represent an accelerated biological aging event for brain-related pathways.
“Menopause is a normal physiological process that every person with ovaries who lives long enough will go through,” said first author Madeline Wood Alexander of the University of Toronto. “We don’t want it to be viewed as a bad thing, but as an opportunity to better understand and possibly modify the biology of brain aging in women.”
The researchers aim to refine the 16-protein signature into a practical clinical blood test—analogous to a midlife lipid panel for heart disease—that could inform risk stratification and early interventions. To advance this goal, Casaletto is launching the Longitudinal Menopause Project, which will follow women through the full transition with frequent blood sampling, multimodal neuroimaging, wearable monitoring and digital cognitive assessments.
Funding: Supported by the National Institutes of Health (R01AG032289, R01AG048234, R01AG063843, RF1AG096165, RF1AG096477, P30AG062422, R01AG072475, K23AG090757, AG027161, UE5NS070680, K23AG084883, and U19AG024904).
Editorial Notes:
- Article edited by a Neuroscience News editor.
- Journal paper reviewed in full and additional context provided by staff.
About this Alzheimer’s Disease Research:
- Media Contact: Victoria Colliver
- Source: UCSF
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): Nature Medicine (Sept 22, 2026). Title: “Blood proteomics of menopause map to brain aging and dementia risk.” Authors listed in the paper include Madeline Wood Alexander and Kaitlin B. Casaletto, among others.
- DOI: 10.1038/s41591-026-04648-4
Abstract
Blood proteomics of menopause map to brain aging and dementia risk
Menopause is a defining biological event in midlife that may influence later neurodegenerative risk, but the mechanisms linking reproductive aging to brain decline have been unclear. Using blood proteomics across multiple cohorts, the authors identified biological changes associated with menopause and evaluated their connection to brain aging.
In a rigorously staged sample of n = 80 pre-, peri- and postmenopausal women aged 43–58 years with serum proteomics, spontaneous menopause was associated with dysregulation of inflammatory, synaptic and metabolic pathways as well as processes related to Alzheimer’s biology—changes that tracked more closely with hormone levels than with chronological age.
Validation in an age-matched sample of n = 2,814 women using plasma proteomics replicated these shifts and revealed broader menopause-related upregulation of inflammatory and catabolic pathways together with signatures of accelerated cellular and organ aging, including brain aging.
Across four independent cohorts of older women (mean ages 60.7–72.1 years; total n = 11,925), higher menopause proteomic scores consistently associated with worse cognitive aging and increased dementia risk. These molecular signatures may help identify biomarkers or therapeutic targets aimed at preserving brain health in midlife women.